IUPAC: 2-(5-methoxy-1H-indol-3-yl)-N,N-dimethylethan-1-amine · C₁₃H₁₈N₂O · MW 218.30 g/mol · CAS 1019-45-0 · ChEMBL7257 (Mebufotenin)
5-methoxy-N,N-dimethyltryptamine. Short-acting "release" tryptamine · the psychoactive principle of Incilius (Bufo) alvarius — the Sonoran Desert / Colorado River toad — and of Anadenanthera snuffs. Context names: the toad, 5-MeO, bufo, jaguar. Distinct from bufotenin (its O-desmethyl metabolite) and from DMT (#003) by its powerful 5-HT1A loading.
5-MeO-DMT is a simple methoxylated tryptamine that engages the serotonergic GPCR family directly — no transporter blockade, no substrate efflux. What separates it from its cousin DMT (#003) is the weighting: 5-MeO-DMT carries unusually high 5-HT1A affinity (Ki ≈ 28 nM at human 5-HT1A; single-digit-to-low-double-digit nM in rodent brain), comparable to or exceeding its 5-HT2A engagement. DMT, by contrast, is 5-HT2A-forward. That 5-HT1A loading is why the 5-MeO experience is often described as less overtly "visual" and more of a totalizing, ego-dissolving "whiteout" release than a DMT-style hallucinatory scene.
High-affinity agonism at 5-HT1A couples to Gi/o, closing adenylyl cyclase and opening GIRK K⁺ channels — hyperpolarizing raphe and cortical neurons. This inhibitory tone is thought to shape 5-MeO-DMT's distinct, less-narrative phenomenology and blunt some of the 5-HT2A visual signature.
Agonism at 5-HT2A drives Gq/PLC → IP₃/DAG signaling in layer-V pyramidal neurons — the shared final common pathway of the classic psychedelics. High-affinity (agonist-state) Ki ≈ 15 nM; the psychedelic core rides on this receptor.
Real ChEMBL data show sub-100 nM affinity across 5-HT2C (42 nM), 5-HT2B (52 nM), 5-HT6 (13 nM) and 5-HT1D (20 nM). It is a promiscuous serotonergic agonist, not a clean single-receptor tool.
CYP2D6 O-demethylates 5-MeO-DMT to bufotenin (5-HO-DMT), itself a serotonergic agonist. CYP2D6 phenotype therefore reshapes the active-metabolite mix — poor metabolizers clear parent drug slowly and generate less bufotenin.
Like DMT, the primary inactivation route is oxidative deamination by MAO-A to 5-methoxyindole-3-acetic acid. This is the linchpin of both its short duration and its lethal interaction profile with MAO inhibitors.
Measurable 5-HT2B agonism (Ki ≈ 52 nM) is the receptor implicated in valvular heart disease with chronic serotonergic agonist exposure — a theoretical concern for frequent, high-dose use.
Vaporized free-base reaches the brain in seconds, producing an extraordinarily intense but brief episode. The pharmacology is receptor-driven — the inverse of cocaine's DAT occlusion or MDMA's SERT reversal — and the 5-HT1A/5-HT2A balance is the mechanistic core of its character.
5-MeO-DMT is defined by route-dependent, MAO-gated kinetics. Vaporized or insufflated, it is not appreciably orally active on its own because gut and hepatic MAO-A deaminate it before it reaches the brain — the same reason oral DMT needs a harmala MAOI. Two clearance routes run in parallel: MAO-A deamination to 5-methoxyindole-3-acetic acid (inactive) and CYP2D6 O-demethylation to bufotenin (active). Because CYP2D6 is polymorphic, exposure and the active-metabolite ratio vary widely between individuals — a genuine dosing hazard for a drug this steep.
Metabolism cascade: one inactivating deamination pathway and one bioactivating demethylation pathway diverge from the parent drug.
Bufotenin (5-hydroxy-DMT, marked ★) is a serotonergic agonist in its own right, so CYP2D6 status modulates not just how fast the parent drug clears but what is circulating during the tail of the experience. CYP2D6 poor metabolizers (~7–10% of Europeans) and anyone on a CYP2D6-inhibiting drug (paroxetine, fluoxetine, bupropion, quinidine) will have altered, generally elevated, parent-drug exposure.
The critical PK fact is the MAO-A dependence: 5-MeO-DMT's short, survivable duration exists only because MAO-A is chewing through it in real time. Remove that enzyme — with a monoamine oxidase inhibitor, including the harmala alkaloids (harmine, harmaline) of ayahuasca/yopo brews — and the drug's exposure, duration, and serotonergic toxicity all rise together, catastrophically. See Harm Reduction below.
The 5-HT1A/5-HT2A balance translates into a subjective profile that regular users distinguish sharply from DMT. Where smoked DMT tends toward vivid, structured, "populated" visionary space, vaporized 5-MeO-DMT is more commonly reported as an overwhelming, formless dissolution — the so-called "release" or "whiteout" — with less discrete imagery and a stronger sense of ego and boundary loss.
Gq signaling on layer-V pyramidal neurons destabilizes the cortical hierarchical-prediction machinery shared by all classic psychedelics — the substrate of the "relaxed beliefs under psychedelics" (REBUS) framework. With 5-MeO-DMT the effect skews toward global unity and boundary dissolution rather than discrete hallucination.
Strong 5-HT1A agonism hyperpolarizes raphe and cortical neurons (Gi/o, GIRK). This inhibitory brake is the pharmacological signature that most separates 5-MeO-DMT from DMT and is thought to underlie its lower visual-content, higher-dissolution character — and its potent hypothermic and neuroendocrine effects in animal models.
Open-label and early-phase work (e.g. inhaled synthetic 5-MeO-DMT / GH001 for treatment-resistant depression) reports rapid, large antidepressant effects after a single dose, exploiting the ultra-short duration to compress a psychedelic session into minutes. This is investigational — administered under monitoring with airway and cardiovascular support, not a validation of unsupervised use.
The acute state carries real autonomic and motor risk: transient hypertension, tachycardia, and — at the peak — loss of postural control, unresponsiveness, and occasional tonic muscle rigidity or seizure-like activity. This is why the drug demands a sober sitter and a padded, hazard-free setting; injuries during the "release" are a leading practical harm.
Tolerance builds acutely and cross-tolerates with other 5-HT2A agonists, but the defining feature is compression: an experience many describe as equal in magnitude to a high-dose oral psychedelic, delivered and largely resolved inside half an hour.
Evidence-based, non-moralistic. 5-MeO-DMT is extraordinarily potent by weight and its safety hinges on two things: getting the dose right, and never touching an MAOI.
| Target | Affinity (Ki) | Rel. | Mechanism |
|---|---|---|---|
|
5-HT1A
Serotonin 1A receptor (HTR1A)
|
28 nM
rat brain 5–11 nM
|
Agonist | |
|
5-HT2A
Serotonin 2A receptor (HTR2A)
|
15 nM*
620 nM (antagonist-state)
|
Agonist | |
|
5-HT6
Serotonin 6 receptor
|
13 nM
|
Agonist | |
|
5-HT1D
Serotonin 1D receptor
|
20 nM
|
Agonist | |
|
5-HT2C
Serotonin 2C receptor
|
42 nM
|
Agonist | |
|
5-HT2B
Serotonin 2B receptor
|
52 nM
|
Agonist |